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Abstract
[11C]GMOM (carbon-11 labeled N-(2-chloro-5-thiomethylphenyl)-N0-(3-[11C]methoxy-phenyl)-N0-methylguanidine) is a
PET ligand that binds to the N-methyl-D-aspartate receptor with high specificity and affinity. The purpose of this first in
human study was to evaluate kinetics of [11C]GMOM in the healthy human brain and to identify the optimal pharma-
cokinetic model for quantifying these kinetics, both before and after a pharmacological dose of S-ketamine. Dynamic
90min [11C]GMOM PET scans were obtained from 10 subjects. In six of the 10 subjects, a second PET scan was
performed following an S-ketamine challenge. Metabolite corrected plasma input functions were obtained for all
scans. Regional time activity curves were fitted to various single- and two-tissue compartment models. Best fits were
obtained using a two-tissue irreversible model with blood volume parameter. The highest net influx rate (Ki) of
[11C]GMOM was observed in regions with high N-methyl-D-aspartate receptor density, such as hippocampus and thal-
amus. A significant reduction in the Ki was observed for the entire brain after administration of ketamine, suggesting
specific binding to the N-methyl-D-aspartate receptors. This initial study suggests that the [11C]GMOM could be used for
quantification of N-methyl-D-aspartate receptors.
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Introduction
N-methyl-D-aspartate (NMDA) receptors belong to a
family of ligand-gated ionotropic channels. NMDA
receptors are important sites of action for glutamate,
the major excitatory neurotransmitter of the central
nervous system. These receptors are tetramer com-
plexes incorporating NR1, NR2, and NR3 subunits,
and each subunit may have its own variations. This,
in turn, results in a variety of diﬀerent NMDA receptor
compositions, each with its own characteristic pharma-
cological properties.1,2 NMDA receptor activation
requires binding of glutamate and either glycine or D-
serine to their respective binding sites. Once the
NMDA receptor is activated, its cation channel opens
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allowing the passage of calcium, sodium, and potas-
sium ions. Phencyclidine (PCP) and other psychoactive
drugs, such as ketamine and dizocilpine (MK-801),
bind to their target site, which is located within the
cation channel of the NMDA receptor.3,4
The NMDA receptor has widespread expression in
the central nervous system and it is involved in many
biological functions, including brain development, syn-
aptic plasticity, and cognitive processes such as memory
and learning.1,5 Alterations in both NMDA receptor
composition and function have been implicated in a
wide range of neurological and psychiatric diseases
such as Alzheimer’s disease (AD), Parkinson’s disease
and Huntington’s disease, addiction disorders, and
schizophrenia.6,7 Pharmaceuticals acting on the
NMDA receptor, such as the partial NMDA antagon-
ist memantine, are approved for treatment of AD
within the U.S. and Europe.8 Imaging the NMDA
receptor with positron emission tomography (PET)
would provide useful information on the role of the
NMDA receptor in the pathophysiology of these
diseases.
Several candidate PET and single photon emission
computerized tomography (SPECT) radioligands have
been synthesized as potential imaging agents for the
NMDA receptor. Most of these ligands, however,
have failed due to either high nonspeciﬁc binding,
poor metabolic stability, or insuﬃcient aﬃnity.2,9
[123I]CNS 1261 and [11C]GMOM have shown the
most promising preclinical results.2,10 [11C]CNS 5161
has been tested in vivo in the human brain but quanti-
ﬁcation was diﬃcult due to fast metabolism and low
radiochemical yield.11,12 Recently, a Fluorine-18
labeled analog of [11C]CNS 5161, [18F]GE-179 has
been proposed as a putative NMDA receptor ligand,
based on its high brain uptake in healthy volunteers.12
This tracer also binds to the PCP site of the NMDA
receptor, just like other diarylguanidines.9 However,
McGinnity et al.12 concluded that further evaluation
of [18F]GE-179 was needed to assess its in vivo speciﬁ-
city. In other words, there is still a need to evaluate
alternative speciﬁc tracers of the NMDA receptor.
In nonhuman primate studies, [11C]GMOM showed
high uptake and was able to demonstrate changes in
modulation of NMDA ion channel activity by
MK801.13 Consequently, [11C]GMOM may have
potential for in vivo quantiﬁcation of the NMDA
receptor in humans. The purpose of the present study
was to evaluate [11C]GMOM in vivo in the human
brain with the primary aim to identify the most appro-
priate kinetic model for quantiﬁcation of [11C]GMOM
binding in healthy volunteers. Moreover, blocking stu-
dies were performed to provide insight in the feasibility
of studying [11C]GMOM binding in the presence of a
pharmacological challenge.
Materials and methods
Subjects
Ten healthy volunteers with an age ranging from 20 to
28 years (mean age 23 years; 9 men, 1 woman) partici-
pated in this study. All subjects were free of medical
and psychiatric illnesses based on medical history,
neurological examination, blood tests (complete blood
count and serum chemistry), urine analysis, and urine
toxicology. The study was approved by the Medical
Ethical Review Committee of the VU University
Medical Center. All subjects provided written informed
consent after complete explanation of the study
procedures.
Radiochemistry
[11C]GMOM was synthesized using an adaptation of
the method of Waterhouse.13 Radiochemical purity
(95.0–99.3%) with no detectable UV impurities was
obtained. Yields were 1470–5560MBq at end of syn-
thesis (3–11%, not corrected for decay) and the speciﬁc
activity (SA) was 97–288GBq mmol1 at end of synthe-
sis. The product was sterile and pyrogen free and man-
ufactured under GMP license NL/H11/0005, issued by
the national competent authorities. A speciﬁc activity
of 77 37GBq mmol1 and a radioactivity concentra-
tion of 391 8MBq [11C]GMOM at the time of injec-
tion was produced.
PET
PET scans were performed on a Gemini TF-64 PET/CT
scanner (Philips Medical Systems, Cleveland, OH,
USA).14 All ten subjects underwent [11C]GMOM
scans at baseline, and six of them also with a second
scan after an S-ketamine challenge. After a bolus injec-
tion of 391 8MBq [11C]GMOM, a 90min dynamic
PET scan was acquired. In addition, a low-dose CT
(20mAs, 80 kVp) was obtained for attenuation correc-
tion. Emission data were reconstructed into 22 frames
(1 15, 3 5, 3 10, 4 60, 2 150, 2 300, 7 600 s)
using a three-dimensional row action maximum likeli-
hood reconstruction algorithm,14,15 including data nor-
malization and corrections for dead time, randoms,
scatter, attenuation, and decay.
As mentioned above, six of the 10 subjects (5M, 1F,
22 2 years) had two dynamic [11C]GMOM scans on the
same day, a baseline scan in the morning followed by a
challenge scan in the afternoon. There were no observed
signiﬁcant diﬀerences in mean injected dose of
[11C]GMOM between baseline and challenge scans (dose
baseline: 387 8MBq, dose challenge: 375 10MBq,
p¼ 0.92, Wilcoxon signed-rank test), nor in SA at time
of injection (SA baseline: 62 30GBqmmol1,
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SA chalenge 60 19GBq mmol1, p¼ 0.08, Wilcoxon
signed-rank test). The minimum time interval between
both scans was 4 h.
S-ketamine challenge
S-ketamine was administered intravenously
(0.3mgkg1) in a pseudo-steady state model with a sub-
acute loading dose. This dose is speciﬁc for the NMDA
receptor as its analgesic eﬀects are not blocked
by naltrexone, a m-opioid antagonist.16,17 First,
S-ketamine was administered in a 40min initial phase
(0.004mgkg1min1) followed by a 10min adjustment
phase (0.0026mgkg1min1). [11C]GMOM was
injected immediately after the adjustment phase.
Subsequently, administration of S-ketamine
(0.0013mgkg1min1) continued for a period of 85min
in the equilibrium phase.
Based on the mean plasma levels of S-ketamine mea-
sured during the blocking scans (56.2 ngml1; molecu-
lar weight: 237.725 gmol1) and an apparent aﬃnity
value of 1 mM for S-ketamine against [3H]MK-801
(Ki), an approximate occupancy value of the NMDA
receptor ion-channel by S-ketamine throughout the
study would be 19% ([Conc]/[Conc]þKD). Our calcu-
lations assume that S-ketamine distributes evenly in
plasma and the brain and does not take into account
binding to plasma proteins.
Input function
During the [11C]GMOM scan, the whole blood radio-
activity concentration was measured continuously
using an online blood sampler detection system
(Veenstra Instruments, Joure, The Netherlands).18
The withdrawal rate was 5mlmin1 during the ﬁrst
5min, followed by 2.5mlmin1 until 65min postinjec-
tion (p.i.). At seven time points (5, 10, 20, 40, 60, 75,
85min p.i.), continuous blood withdrawal was inter-
rupted brieﬂy to allow for collection of manual arterial
blood samples (10ml). Following each sample, the can-
nula was ﬂushed with heparinized saline to prevent
clotting. The manual samples were used to measure
plasma to whole blood (P/WB) radioactivity ratios,
and radioactive fractions of [11C]GMOM and its radio-
active metabolites in plasma.
Plasma samples were analyzed using solid-phase
extraction combined with HPLC using oﬀ-line radio-
activity detection.19 Three fractions were determined:
[11C]GMOM, nonpolar metabolites, and polar metab-
olites. One minus the polar fraction was used as a sur-
rogate for the parent fraction, as estimation of intact
[11C]GMOM was not robust due to fast metabolism
and the amount of nonpolar metabolites was very
small and unreliable (1.5 2.0% at 90min p.i.).
Each plasma input function was corrected for blood-
to-plasma ratio, (polar) metabolites, and time delay.
The manual arterial blood samples were also used for
determining the S-ketamine concentration in plasma.
These sample calculations were performed in duplicate.
The area under the S-ketamine concentration–time
curve was estimated by means of the trapezoidal rule.
Regions of interest (ROI) delineation
For anatomical delineation of ROIs, a structural mag-
netic resonance image (MRI) was obtained on a 1.5 T
Sonata scanner (Siemens Medical Solutions, Erlangen,
Germany). Scanning included a coronal T1-weighted
scan (echo time 3.97ms, repetition time 2700ms, ﬂip
angle 8, 160 coronal slices, voxel size 1.0 1.5
1.0mm3). T1-weighted MRIs were co-registered to an
average PET image (5–16 frames) using VINCI soft-
ware.20 The co-registered MRIs were segmented into
gray matter, white matter, and extra-cerebral ﬂuid,
and regional time activity curves (TACs) were extracted
using PVE-lab.21–23 For the present study, eight ROIs
were redeﬁned by combining the ROIs extracted from
the PVE-lab. The selection of ROIs was based on the
widespread NMDA receptor availability in the brain:
frontal, temporal, occipital, and parietal cortex, hippo-
campus, thalamus, striatum, and cerebellum, as well as
whole brain gray matter.
Kinetic modeling
A total of seven compartmental models were evaluated:
standard singe-tissue (1T2k), irreversible (2T3k), and
reversible (2T4k) two-tissue compartmental models,
both with and without an additional (ﬁt-)parameter
for fractional blood volume (VB). In addition, a dual
input compartmental model (D1T2k) with blood
volume fraction (ﬁt-)parameter was included to evalu-
ate the possibility that polar metabolites enter the brain
and have impact on the kinetics observed. Eﬀects of
scan duration on model preference were tested by
repeating the procedure mentioned above for the initial
60, 50, and 40min of scan data.
Statistics
The optimal tracer kinetic model for describing
[11C]GMOM kinetics was determined using the
Akaike information criterion (AIC).24 The nonpara-
metric Wilcoxon signed-rank test without multiple cor-
rections was used to assess whether there were
signiﬁcant diﬀerences in pharmacokinetic parameters
(estimated from the preferred model) between baseline
and S-ketamine scans. To calculate the signiﬁcance of
the postketamine decrease in Ki at the level of the whole
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brain, linear mixed eﬀect modeling was performed using
SPSS software, and considering regions, patients, and
conditions (i.e. before and after challenge) as factors.
In this statistical test, regions and conditions were con-
sidered as ﬁxed and patients as random factors, respect-
ively. For all analyses, p< 0.05 was considered to be
signiﬁcant and 0.05<p< 0.1 as a trend level.
Results
Input function and plasma metabolite analysis
Figure 1(a) shows the average (SD) parent fractions,
polar fractions, and plasma to whole blood ratios for
all available scans (N¼ 15). [11C]GMOM has fairly
rapid metabolism, which is shown by the fast decrease
in parent fraction from 0.80 0.06 at 5min p.i. to
0.21 0.08 at 60min p.i. Parent fractions at the last
two time points (75 and 90min p.i.) were too small
for reliable estimates. There were no signiﬁcant diﬀer-
ences in tracer metabolism between baseline and
S-ketamine scans as indicated by the Wilcoxon
signed-rank test. One pair out of the six paired baseline
and ketamine challenge scans was excluded from this
statistical analysis due to technical problems encoun-
tered during metabolite analysis for one of the scans
(baseline scan). Input functions of baseline and keta-
mine challenge scans for a typical subject are illustrated
in Figure 1(b) and Supplementary Figure 1.
S-ketamine
S-ketamine was administered in a pseudo-steady state.
During scans subjects were able to tolerate the
Figure 1. (a) Mean ( SD) of parent, polar fractions, and plasma to whole blood ratios for all available scans (N¼ 15), parent
fractions for 75 and 90min could not be measured. (b) Typical metabolite corrected plasma input functions (Y-axis, logarithmic scale)
for baseline and S-ketamine challenge scans.
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administered S-ketamine dose. Mean S-ketamine con-
centrations of the six subjects started at 62 ngml1 at
5min p.i. and decreased to 38 ngml1 at the end of the
scan (Figure 2).
ROI data analysis
A representative example of [11C]GMOM brain uptake
in a healthy volunteer is provided in Figure 3. Similar
to the known expression of NMDA, a whole brain
activity distribution was observed. Lower brain activity
is seen after the S-ketamine challenge than in the base-
line condition at all-time points p.i. (Figure 3). Figure 4
shows typical TACs corrected for injected activity
(%IDml1) from the eight ROIs and whole brain
gray matter. Radioactivity concentrations were highest
in thalamus and striatum, both at baseline and after
S-ketamine.
Kinetic modeling
A total of 15 scans (nine baseline, six S-ketamine) were
used to identify the optimal kinetic model. Figure 5
illustrates that the irreversible two-tissue compartment
model with blood volume parameter (2T3k_VB) was
the preferred model based on AIC. Less preference
was observed for the dual input model with blood
volume fraction parameter (D1T2k_VB). There was
no diﬀerence in model preference between baseline
and S-ketamine scans. In addition, after separating
ROIs in small (<2ml), medium (2–5ml), and large
(>5ml) ones, no eﬀect of region size on model prefer-
ence was seen. All regions ﬁtted best to the 2T3k_VB
model, although this preference was most prominent
for large regions.
With decreasing scan duration, model preference
slowly shifted toward the reversible single-tissue
model with additional blood volume parameter
(1T2k_VB). For the majority of ROIs, the 2T3k_VB
was still preferred in case of 60min datasets. For the
50min datasets, however, there was equal preference
for 1T2k_VB and 2T3k_VB models, and for the
40min dataset the 1T2k_VB was preferred.
Since 2T3k_VB was the preferred model, the primary
outcome parameter was the net inﬂux rate constant Ki
(Ki¼ (K1k3)/(k2þk3)). Ki values were compared
between baseline and S-ketamine challenge scans in
order to determine the speciﬁc signal of [11C]GMOM
for the NMDA receptor. Mean nondisplaceable distri-
bution volumes (VND¼K1/k2) of baseline and chal-
lenge conditions were compared to assess the eﬀect on
Figure 2. Mean (SD) plasma levels of S-ketamine in six
healthy volunteers after intravenous administration of
0.3mg kg1 S-ketamine in a pseudo-steady state manner.
Figure 3. Transaxial image of [11C]GMOM uptake (Bqml1) in a healthy volunteer at different times postinjection (p.i.), at baseline
(top) and after S-ketamine challenge (bottom).
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Figure 4. Time activity curves (TACs) corrected for injected activity (%IDmL1) from selected regions: hippocampus, thalamus,
striatum, cerebellum, frontal, temporal, parietal and occipital cortex, for a typical subject (a) at baseline, (b) after S-ketamine, and (c)
from whole brain gray matter at baseline and after S-ketamine.
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the nondisplaceable compartment. In addition, poten-
tial diﬀerences in mean rate constant K1 between base-
line and S-ketamine data were investigated to assess
whether S-ketamine had an eﬀect on the inﬂux of
[11C]GMOM. Results obtained using the 2T3k_VB
model are summarized in Table 1. Baseline Ki values
were highest in hippocampus and thalamus, followed
by frontal, parietal and occipital cortex, striatum, tem-
poral cortex, and cerebellum (Table 1). Figure 6 shows
diﬀerences in Ki values for all ROIs averaged between
baseline (N¼ 9) and S-ketamine (N¼ 6) scans.
After S-ketamine challenge, a signiﬁcant decrease in
Ki (linear mixed eﬀects models, factors are ROI, patient
and condition (before and after challenge), p< 0.0001)
was observed at the whole brain level. The linear mixed
eﬀects model showed no interaction between ROI and
condition, suggesting that all considered ROIs showed
a similar change in Ki (Figure 6). It should be noted
that, after S-ketamine administration, Ki values
increased in one of the subjects (>75% for all ROI),
but no reason for this unexpected observation could be
found. When excluding this outlier, the percentage
change in the mean Ki of total brain gray matter was
66 23% and, in thalamus and hippocampus of
79 24% and 70 12%, respectively.
No signiﬁcant diﬀerence in VND was observed in
whole brain gray matter (Wilcoxon signed-rank test,
p¼ 0.14), as well as in most other ROIs. Nevertheless,
a signiﬁcant increase in VND in the S-ketamine condi-
tion was found in cerebellum and hippocampus
(Wilcoxon signed-rank test, p¼ 0.04). Similar results
when excluding the outlier was observed, however
with more regions showing a signiﬁcant increase in
the VND. The mean rate of transport K1 ranged from
0.36 to 0.52mlcm3min1, reﬂecting high extraction of
[11C]GMOM. No signiﬁcant diﬀerences in K1 were
found between baseline and S-ketamine scans for all
ROIs both including or excluding the outlier
(Table 1). On performing linear mixed eﬀects model
analysis for VND and K1, a signiﬁcant but small
increase (10% for VND and 7% for K1) after the chal-
lenge was observed.
Discussion
To the best of our knowledge, this is the ﬁrst study
assessing the potential of [11C]GMOM for in vivo
quantiﬁcation of NMDA receptors in the human
brain. Results indicate that the irreversible two-tissue
compartment model with additional fractional blood
volume (ﬁt) parameter is the most appropriate model
for kinetic analysis of [11C]GMOM data. The highest
baseline Ki values were seen in hippocampus and thal-
amus, followed by frontal, parietal and occipital cor-
tices, and striatum, and with the lowest values in
temporal cortex and cerebellum. This spatial distribu-
tion is in line with preclinical results in rat and baboon
brain.13 Furthermore, uptake of [11C]GMOM had a
spatial distribution that was consistent with the
NMDA receptor distribution in postmortem human
brain,25 suggesting preferential uptake in regions with
high NMDA receptor density.
A limited number of NMDA receptor ligands have
been tested in humans, but they were either inappropri-
ate for imaging purposes or they have not been fully
characterized. At present, there appears to be no
NMDA receptor tracer that is clearly better than
others. The moderate lipophilicity of GMOM
Figure 5. Number of preferred fits (y-axis) per model (x-axis) according to AIC for the 90min datasets.
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(log P¼ 2.34)26 is similar to that of [11C]CNS5161 (log
P¼ 1.92),9 and GE-179 (logD7.4¼ 2.49).12 Although
[11C]GMOM has a higher aﬃnity (Kd¼ 5.2 0.3 nM)26
than [11C]CNS5161 (Kd¼ 1.9 0.3 nM) and [18F]GE-179
(Kd¼ 2.4 nM)12 and the SPECT ligand [123I]CNS1261
(Kd¼ 4.2 0.4 nM),9 all suﬀer from rapid metabolism.
Mean parent fractions of [11C]GMOM and [18F]GE-179
are similar with only 50% remaining at 20min postinjec-
tion. In addition, TACs of [11C]GMOM and [18F]GE179
are similar, showing a peak uptake at around 20min and
a prolonged modest decrease until 90min. However, the
rate of metabolism of [11C]GMOM and [18F]GE179
seems to be slower than that of [11C]CNS 5161 and
[123I]CNS1261. To examine which tracer is superior,
more studies are needed, for example a study that meas-
ures the eﬀects of a ketamine challenge for [18F]GE-179
and [11C]CNS 5161.
Pharmacokinetic evaluation indicated that the two-
tissue irreversible model with fractional blood volume
parameter was the preferred model irrespective of con-
dition (baseline or S-ketamine) or region size, although
the preference was more prominent in large regions.
From Figure 1, it is more intuitive to consider reversible
than an irreversible kinetics. Nevertheless, from the
data it seems that GMOM has an irreversible compo-
nent with very slow kinetics, which is illustrated by high
preference for the 2T3k_VB model based on the AIC
comparison. Whole brain TACs together with the best
ﬁts obtained using 1T2k_VB, 2T3k_VB and 2T4k_VB
models (Supplementary Figure 2) also hint at this pref-
erence. Observing the ﬁts it seems that 1T2k_VB model
also ﬁts the data well although considering individual
compartments curves (free, nondisplaceable, and spe-
ciﬁc), particularly 2T3k_VB, a contribution of irrevers-
ible compartment (blue curve in the 2T3k_VB ﬁt,
Supplementary Figure 2) could be seen. The irreversibleT
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Figure 6. Bar plots (mean with SD error bars) illustrating the
effect of S-ketamine on Ki values for all regions of interests
investigated. The outlier subject has been excluded for this plot.
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speciﬁc compartment is very slow but also small. In
order words, the curves observed are dominated by
the nondisplaceable binding, which has reversible kin-
etics. In addition, k3 (using 2T3k_VB) was estimated
reliably. The irreversible model was also able to capture
the decrease in net inﬂux rate, Ki, after ketamine chal-
lenge. Both k3 values and the TACs for the irreversible
compartment (blue curve in the 2T3k_VB ﬁt,
Supplementary Figure 2) illustrate very slow and small
irreversible kinetics of [11C]GMOM. Therefore, it could
be anticipated that scans with substantial longer duration
than 90minmight indeed have shown an increasing tail in
the brain TACs.Moreover, based on the present results a
scan duration of at least 90min is recommended for
future [11C]GMOM studies, since there was a shift in
model preference with decreasing scan duration indicat-
ing that the second tissue compartment only becomes
apparent at later (>60min) scanning times.
As discussed previously and based on previous
reports, preference for the irreversible model was not
expected.12,27 A possible explanation for this ﬁnding
might be the inﬂux of (polar) metabolites into the
brain. It is not known whether radiolabelled metabol-
ites of [11C]GMOM are able to cross the blood–brain
barrier and enter the brain. Therefore, an additional
model including a single tissue compartment for labeled
polar metabolites (using the polar metabolites as input
function) was investigated. This (dual input) model
with blood volume parameter (D1T2k_VB) used two
input functions, one for parent [11C]GMOM, the
other for radiolabelled polar metabolites. The model
has been described previously by Yaqub et al.28 with
respect to the analysis of dynamic [18F]FDDNP scans.
In the present study, the metabolite input function was
based on polar metabolites only, thereby ignoring the
(small) fraction of nonpolar metabolites. However, this
dual plasma input model was not preferred over the
standard irreversible model, neither could it detect the
expected eﬀects of the S-ketamine challenge
(Supplementary Table 1).
Studies have shown a clear association between the
aﬃnity of ion-channel blockers for the PCP site and the
degree of trapping within the NMDA receptor chan-
nel.29 From a neuropharmacological perspective it is
reasonable to assume that a high aﬃnity ligand, such
as [11C]GMOM, might stay 90min or longer at the
PCP site of the NMDA receptor, and exhibit irrevers-
ible binding during the course of a 90min PET
study.27,30–32
Ki values derived from the 2T3k_VB model were
compared between baseline and S-ketamine conditions
for all gray matter ROIs included in this study. The
expected reduction in tracer accumulation after the
S-ketamine challenge was observed at whole brain
with high signiﬁcance and at a trend level in thalamus
and hippocampus. It is interesting to note that thal-
amus and hippocampus are both regions with high
NMDA receptor density.25 In contrast to the other sub-
jects, Ki values in the ﬁfth subject increased after S-
ketamine administration, but no reason could be
found for this unexpected and counterintuitive result.
No substantial diﬀerence in VND was observed
before and after challenge in most ROIs, although a
signiﬁcant increase (nonparametric Wilcoxon signed-
rank test) in VND was found in some ROIs after the
challenge. Also no substantial diﬀerence in rate con-
stant K1 was found between pre- and post-S-ketamine
administration scans, which indicates that there is
almost no change in perfusion and/or extraction due
to S-ketamine. However on performing linear mixed
model analysis for VND and K1, signiﬁcant but small
increases (10% for VND and 7% for K1) were found as
a result of the challenge. These increases will not aﬀect
the conclusion. In fact, it will further support the notion
that the signiﬁcant decrease (linear mixed model ana-
lyses) in Ki reﬂects a decrease of tracer accumulation
in the speciﬁc compartment (as an increase in K1 and
VND alone would have resulted in an increase in Ki).
In line with other PET and SPECT ligands of the
PCP site,12,27 [11C]GMOM was metabolized rapidly. As
a result, estimation of the polar metabolite fraction was
more robust than that of the parent fraction and since
the nonpolar metabolite fraction was small, 1 minus the
polar fraction was used as a surrogate of the parent
fraction. It is possible in case of a very high nonpolar
metabolite fraction at earlier time points, that the 1
minus polar fraction would result in a substantial over-
estimation of the parent fraction. Supplementary
Figure 3 shows that the level of nonpolar metabolites
is relatively small at all-time points. Nevertheless, it is
also clear that ignoring nonpolar metabolites will result
in some bias, which needs to be addressed in future
studies. Yet, this study showed that robust plasma
input model ﬁts could be obtained and that the eﬀects
of the S-ketamine challenge were well captured using
plasma input-derived Ki values. An alternative would
be a reference model approach but NMDA receptors
are important sites of action for glutamate with wide-
spread expression in the whole brain. This is also
observed in the present work for all ROI studied.
Using in vitro radioligand binding techniques, it has
been well established in both rodent33 and postmor-
tem human34 brain tissue that there are no regions
devoid of NMDA receptors. Therefore, to our best of
knowledge, a reference model approach might not be
valid for NMDA receptor ligands. Additional limita-
tion of this study is the small sample size and lack of
test–retest data. Further studies are needed to assess
the within-subject variability in a larger number of
subjects.
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Conclusion
The plasma input irreversible two-tissue compartment
model with additional fractional blood volume is the
method of choice for quantiﬁcation of [11C]GMOM
binding, but a scan duration of 90min or longer is
required for robust results. This initial study shows
that [11C]GMOM could be used for imaging and quan-
tifying the NMDA receptor.
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